Publications by authors named "Hidee Ishii"

Beta-tricalcium phosphate (β-TCP) serves as a bone substitute in clinical practice because it is resorbable, biocompatible, osteointegrative, and osteoconductive. Particles of β-TCP are also inflammatory mediators although the mechanism of this function has not been fully elucidated. Regardless, the ability of β-TCP to stimulate the immune system might be useful for immunomodulation.

View Article and Find Full Text PDF
Article Synopsis
  • The study explores how a fragrant environment (FE) containing α-pinene affects tumor growth in melanoma mice, revealing a ~40% reduction in tumor size.
  • Exposure to the FE led to decreased leptin levels and increased sympathetic nervous activity, while certain immune cells (B cells, CD4 T cells, CD8 T cells, and natural killer cells) were found to be more abundant.
  • These findings suggest that the FE may enhance immune response and activate key neurohormonal pathways, potentially offering a mechanism for how environmental factors can influence cancer outcomes.
View Article and Find Full Text PDF

Beta-tricalcium phosphate (β-TCP) is widely used for bone substitution in clinical practice. Particles of calcium phosphate ceramics including β-TCP act as an inflammation mediators, which is an unfavorable characteristic for a bone substituent or a prosthetic coating material. It is thought that the stimulatory effect of β-TCP on the immune system could be utilized as an immunomodulator.

View Article and Find Full Text PDF
Article Synopsis
  • - Calcium phosphate (CaP) ceramics, especially β-TCP, are popular in medical procedures like bone grafts and tumor surgeries, but β-TCP has the unique potential to stimulate immune responses against tumors.
  • - A study discovered that injecting β-TCP into mice led to significant immune cell migration to the injection site and increased activity in immune cells, indicating that β-TCP triggers a strong immune reaction.
  • - The results suggest that β-TCP could serve not only in bone repair but also as an innovative treatment to enhance cancer therapy by boosting the body's immune response.
View Article and Find Full Text PDF

Proneurotensin/neuromedin N (proNT/NMN), the precursor of neurotensin (NT) and neuromedin N (NMN), is produced by cancer tissues derived from the pancreas and colon. NT stimulates tumor growth and proliferation through its receptors; however, little is known about the precursor molecule in cancer tissues. We previously demonstrated that proNT/NMN is secreted from small cell lung carcinoma (SCLC) cell lines in serum-free conditioned medium, but not from non-small cell lung carcinoma (NSCLC) cell lines.

View Article and Find Full Text PDF

Stress is believed to be harmful to not only mental but also physical health. However, proving a link between stress and disease is difficult. A recent study reported that an environmental enrichment reduced cancer growth via the hypothalamic-pituitary-adrenal axis and leptin.

View Article and Find Full Text PDF

Fms-like tyrosine kinase 3 ligand ([Flt3 ligand], FL) stimulates proliferation and development of a wide range of hematopoietic cells including hematopoietic stem cells and myeloid and lymphoid progenitor cells. FL also has been shown to have anti-tumor effects in a variety of in vivo tumor models. In this study, the effect of FL against tumor growth was investigated in the COLO-205 human colon tumor xenograft model.

View Article and Find Full Text PDF

Signal transducer and activator of transcription (STAT)3, a member of a family of DNA-binding molecules mediating numerous physiological and oncogenic signaling pathways, is a novel target in cancer cells which show high phosphorylation of STAT3. Recently, we identified a novel small-molecule inhibitor of STAT3 dimerization, STX-0119, as a cancer therapeutic. We investigated the mechanisms responsible for the antitumor activity in vitro and in vivo through numerous biochemical and biological assays.

View Article and Find Full Text PDF

The signal transducer and activator of transcription 3 (STAT3) is considered to be an attractive therapeutic target for oncology drug development. We identified a N-[2-(1,3,4-oxadiazolyl)]-4-quinolinecarboxamide derivative, STX-0119, as a novel STAT3 dimerization inhibitor by a virtual screen using a customized version of the DOCK4 program with the crystal structure of STAT3. In addition, we used in vitro cell-based assays such as the luciferase reporter gene assay and the fluorescence resonance energy transfer-based STAT3 dimerization assay.

View Article and Find Full Text PDF

Classical cancer immunotherapy utilizes the immune response against microbial components, and a sequence of immune responses produce antitumor effects. The identification of mammalian Toll-like receptors (TLRs), receptors for microbial components, has shed light on antigen recognition by the innate immune system and provided a molecular basis for our understanding of the relationship between innate immunity and antitumor activity. However, accumulating evidence has revealed another important role of TLRs in maintaining tissue homeostasis and has also shown that tumor cells utilize this function to create favorable conditions for growth and survival, suggesting that TLR signaling acts as a double-edged sword in cancer therapy.

View Article and Find Full Text PDF